Volume-Based Growth Tumor Kinetics as a Prognostic Biomarker for Patients With EGFR Mutant Lung Adenocarcinoma Undergoing EGFR Tyrosine Kinase Inhibitor Therapy: A Case Control Study

Cancer Imaging - United Kingdom
doi 10.1186/s40644-016-0063-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Correction To: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined With Chemotherapy Delay Brain Metastasis in Patients With EGFR‑Mutant Lung Adenocarcinoma

Targeted Oncology
Cancer ResearchOncologyPharmacology
2019English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy
OncologyPharmacology
2015English

Glucosylated Epigallocatechin Gallate (EGCG) Derivatives Combined With EGFR Tyrosine Kinase Inhibitor Overcome Resistance in EGFR T790M Mutant Lung Cancer

Biomedical Journal of Scientific & Technical Research
2019English

P1.13-28 the Functional MDM4 Genetic Polymorphsim as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Squamous Cell Transformation and EGFR T790M Mutation as Acquired Resistance Mechanisms in a Patient With Lung Adenocarcinoma Treated With a Tyrosine Kinase Inhibitor: A Case Report

Oncology Letters
Cancer ResearchOncology
2017English

LAPTM4B Is a Novel Diagnostic and Prognostic Marker for Lung Adenocarcinoma and Associated With Mutant EGFR

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

MA24.05 Baseline Spatial Heterogeneity of T790M in Tyrosine Kinase Inhibitor Naïve EGFR-Mutant Lung Adenocarcinomas

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Mechanisms of Acquired Resistance to EGFR-tyrosine Kinase Inhibitor in Korean Patients With Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2013English

Different Mutational Characteristics of the Subsets of EGFR-tyrosine Kinase Inhibitor Sensitizing Mutation-Positive Lung Adenocarcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy